Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Nonsteroidal anti-inflammatory drugs
Cancer, 10/16/09

Zell JA et al. – When used regularly or over a prolonged duration before CRC diagnosis, NSAIDs are associated with decreased mortality among female CRC patients.

Methods

Women aged < 85 years participating in California Teachers Study, without prior CRC diagnosis at baseline (1995-1996), and who were diagnosed with CRC during follow-up through December 2005, were eligible for analysis of the association between prediagnosis NSAID use and mortality
NSAID use (including aspirin and ibuprofen) collected through self-administered questionnaire
Cancer occurrence identified through California Cancer Registry linkage
Multivariate Cox proportional hazards regression models were used to estimate HR for death and 95% confidence intervals (95% CIs)

Results

Among 621 CRC patients , 64% reported no prediagnosis regular NSAID use, 17% reported use of 1 to 6 days/week, and 20% reported daily use
Duration of NSAID use < 5 years reported by 17% of patients and use of 5 years was reported by 18%
Regular prediagnosis NSAID use (1-3 days/week, 4-6 days/week, and daily) versus none was associated with improved overall survival (OS) (HR, 0.71; 95% CI, 0.53-0.95) and CRC-specific survival (HR, 0.58; 95% CI 0.40-0.84) after adjustment for clinically relevant factors
Prediagnosis NSAID use ≥ 5 years (vs none) found to be associated with improved OS (HR, 0.55; 95% CI, 0.37-0.84) and CRC-specific survival (HR, 0.40; 95% CI, 0.23-0.71) in adjusted analyses

<< Previous
Menopausal symptoms in women undergoing chemotherapy-induced and...

Next >>
Cediranib, an oral inhibitor of vascular endothelial growth...